Cerivastatin: marketing discontinued

April 2001
WHO Drug Information;2001, Vol. 15 Issue 2, p77
Academic Journal
Reports on the decision of the manufacturer of cerivastatin sodium (Baycol) to discontinue the marketing and distribution of cerivastatin in the United States. Post marketing reports of muscle weakness and rhabdomyolysis; Rare cases of rhabdomyolysis with all statins.


Related Articles

  • Advertisements for atorvastatin were misleading to women. Dobson, Roger // BMJ: British Medical Journal (International Edition);10/25/2008, Vol. 337 Issue 7676, p954 

    The article reports that advertisements for the lipid lowering drug atorvastatin, known as Lipitor, were misleading in that they failed to disclose the absence of benefits for women. The pharmaceutical company Pfizer is accused of failing to disclose critical portions of the U.S. Food and Drug...

  • BRAND OF THE YEAR CRESTOR. Armstrong, Walter // Pharmaceutical Executive;Feb2009, Vol. 29 Issue 2, p30 

    The article focuses on AstraZeneca's statin Crestor which received the Brand of the Year award of "Pharmaceutical Executive" in the U.S. Accordingly, its sales are a marvel to think that it has wreaked havoc on the $34 billion cholesterol market. Crestor's success is said to have derived from...

  • Aspirin-a-day advice unheeded, survey finds.  // Journal of Business (10756124);12/8/2005, Vol. 20 Issue 25, pB7 

    The article discusses the reduced number of physicians prescribing the use of aspirin for heart diseases. The research was conducted by the Stanford University School of Medicine. The research found that many doctors are prescribing the statin drugs. Statin drugs help reduce the amount of bad...

  • Statins market roiled as generic Zocor bites Lipitor. McGuire, Stephen // Medical Marketing & Media;Oct2007, Vol. 42 Issue 10, p8 

    The article reports on the declining market share of Pfizer Inc.'s Lipitor following the introduction of the generic drug Zocor or simvastatin in the U.S. According to market data, sales of Lipitor declined by 6% for the first half of 2007 and its market share by 10% as compared to the same...

  • Intelligence. Koroneos, George // Pharmaceutical Representative;Feb2009, Vol. 39 Issue 2, p8 

    The article offers news briefs related to the pharmaceutical industry in the U.S. The Pharmaceutical Research and Manufacturers of America has modified its guidelines for advertising of prescription drugs. The U.S. Food and Drug Administration has backed Vytorin in reducing arterial plaque in...

  • Super Boy Has Massive Muscles.  // Current Health 2;Nov2004, Vol. 31 Issue 3, p6 

    Deals with the effect of the protein myostatin on the skeletal muscle.

  • Implementation of a therapeutic-interchange clinic for HMG-CoA reductase inhibitors. Grace, Karen A.; Sweicki, Jennifer; Hyatt, Richard; Gibbs, Henny; Jones, David l.; Sheikh, Munazza; Spain, John; Maneval, Kent W.; Viola, Rebecca; Taylor, Allen J. // American Journal of Health-System Pharmacy;6/1/2002, Vol. 59 Issue 11, p1077 

    Focuses on the implementation of a therapeutic-interchange clinic for HMG-CoA reductase inhibitors. United States Department of Defense's use of cerivastatin and simvastatin.

  • FDA Drug Approvals: Crestor.  // Formulary;Sep2003, Vol. 38 Issue 9, p509 

    Offers information on the pharmacology of the resuvastatin drug Crestor. Approval for treatment of lipid disorders; Performance of the drug in the treatment of patients with hypercholesterolemia; Contraindication of resuvastatin in liver disease or persistent elevations of serum transaminases.

  • Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes.  // New England Journal of Medicine;2/16/2006, Vol. 354 Issue 7, p778 

    A correction to the article "Intensive Versus Moderate Lipid Lowering with Statins After Acute Coronary Syndromes" that was published in the April 8, 2005 issue is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics